ImPact Biotech

Executive Summary

ImPact Biotech is an Israeli clinical-stage biopharmaceutical company pioneering Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive laser-activated drug delivery system designed to ablate solid tumors with surgery-like efficacy and reduced morbidity. The company's lead program targets upper-tract urothelial carcinoma (UTUC), with additional development in lung, esophageal, and pancreatic cancers. Founded in 2020, ImPact leverages a differentiated modality that combines a photosensitizing drug with precise light activation to selectively destroy tumor tissue while sparing healthy parenchyma. This approach has the potential to address significant unmet needs in oncology, particularly for patients who are poor candidates for surgery or conventional therapies. Currently, ImPact is advancing through Phase 1 clinical trials, aiming to establish safety and preliminary efficacy signals across multiple indications. The company's focus on a versatile platform technology, coupled with a pragmatic clinical development strategy, positions it as a compelling player in the photodynamic therapy space. With a lean organization of 50-200 employees and a clear value proposition, ImPact Biotech is poised to generate pivotal data that could unlock substantial value for patients and investors alike.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 safety and efficacy data readout for upper-tract urothelial carcinoma60% success
• Q4 2026Enrollment completion and interim data for Phase 1/2 trial in pancreatic cancer50% success
• TBDStrategic partnership or licensing deal for lung cancer indication30% success